Effectiveness and Safety of Radium-223 Dichloride
| AUTHOR | Asensio Ruiz, Ma Alejandra; Soria Soto, Manuel |
| PUBLISHER | Our Knowledge Publishing (10/20/2023) |
| PRODUCT TYPE | Paperback (Paperback) |
Description
Radium-223 dichloride (Ra-223) is an alpha particle-emitting radiopharmaceutical whose licensed indication in patients with castration-resistant prostate cancer with bone metastases (CRPCm) was modified in June 2018, due to the appearance of drug-drug interactions with common drugs in CRPCm such as abiraterone and prednisone/prednisolone. Thus, it was restricted to use in monotherapy or combination with luteinizing hormone-releasing hormone analogues, becoming third-line treatment in patients with CRPCm, for which evidence on its effectiveness and safety in this new context is lacking.
Show More
Product Format
Product Details
ISBN-13:
9786206581642
ISBN-10:
6206581640
Binding:
Paperback or Softback (Trade Paperback (Us))
Content Language:
English
More Product Details
Page Count:
60
Carton Quantity:
118
Product Dimensions:
6.00 x 0.14 x 9.00 inches
Weight:
0.22 pound(s)
Country of Origin:
US
Subject Information
BISAC Categories
Medical | Pharmacology
Descriptions, Reviews, Etc.
publisher marketing
Radium-223 dichloride (Ra-223) is an alpha particle-emitting radiopharmaceutical whose licensed indication in patients with castration-resistant prostate cancer with bone metastases (CRPCm) was modified in June 2018, due to the appearance of drug-drug interactions with common drugs in CRPCm such as abiraterone and prednisone/prednisolone. Thus, it was restricted to use in monotherapy or combination with luteinizing hormone-releasing hormone analogues, becoming third-line treatment in patients with CRPCm, for which evidence on its effectiveness and safety in this new context is lacking.
Show More
Your Price
$57.00